Reduced IgG titers against pertussis in rheumatoid arthritis: Evidence for a citrulline-biased immune response and medication effects

Caitlyn L. Holmes¹,², Chloe G. Peyton¹, Amy M. Bier¹, Tobias Z. Donlon¹, Fauzia Osman¹, Christie M. Bartels¹, Miriam A. Shelef¹,³*

¹ Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America, ² Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America, ³ William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States of America

* mshelef@medicine.wisc.edu

Abstract

Background
The antibody response to pertussis vaccination in rheumatoid arthritis is unknown, a concerning omission given the relatively low efficacy of the pertussis vaccine, a rise in pertussis infections, and a general increased susceptibility to infection in rheumatoid arthritis. Additionally, the contributions from an intrinsically dysregulated immune system in rheumatoid arthritis and immune-suppressing medications to the response to pertussis vaccination is poorly defined. This study examines antibody titers against pertussis in vaccinated rheumatoid arthritis patients and controls as well as evaluates potential contributions from demographic factors, immune suppressing medications, and reactivity against citrullinated pertussis.

Methods
Serum IgG titers against native and citrullinated pertussis and tetanus were quantified by enzyme-linked immunosorbent assay in rheumatoid arthritis subjects and controls who were vaccinated within 10 years. Titers were compared by t-test and percent immunity by Fisher’s exact test. Multivariable logistic regression was used to identify clinical factors that correlate with native pertussis titers.

Results
Compared to controls, rheumatoid arthritis subjects had lower titers against pertussis, but not tetanus, and reduced immunity to pertussis. These results were even more prominent at 5–10 years post-vaccination, when rheumatoid arthritis patients had 50% lower titers than controls and 2.5x more rheumatoid arthritis subjects were not considered immune to pertussis. Multiple logistic regression demonstrated that female sex and methotrexate
use, but not TNF inhibiting medications, correlated with reduced immunity to pertussis. Finally, rheumatoid arthritis patients had higher IgG titers against citrullinated pertussis than native pertussis.

Conclusions

Pertussis titers are lower in vaccinated rheumatoid arthritis patients with evidence for contributions from female sex, a citrulline-biased immune response, and methotrexate use.

Introduction

Patients with rheumatoid arthritis, a chronic progressive autoimmune disease with a lifetime risk of about 3% [1], are at increased risk for infection [2], but data are mixed regarding response to vaccination. Following influenza or pneumococcus immunization, which are both recommended for rheumatoid arthritis patients given overall efficacy [3, 4], rheumatoid arthritis patients have a normal response to some vaccine strains and serotypes and an impaired response to others [5–8], which may be improved by the use of adjuvant [9]. Also, patients with rheumatoid arthritis have similar antibody levels against tetanus compared to controls, but differences in antibody affinity and subclass [10]. Given the variability seen in the response of rheumatoid arthritis patients to different vaccines, it is necessary to separately assess the response to each vaccine. However, no studies have addressed the antibody response to the pertussis vaccine in rheumatoid arthritis.

_Bordetella pertussis_ is a bacterial species that causes “whooping cough,” a severe respiratory infection characterized by violent and uncontrollable coughing associated with high rates of rib fractures and syncope in adults and apnea, pneumonia, and death in babies. An estimated 16 million cases of pertussis were reported globally in 2008 and incidence in the United States has been rising since 2002 [11, 12]. For adults in the United States, vaccination against pertussis is typically part of the Tdap (tetanus, diphtheria, and pertussis) vaccine, which is recommended to be administered every 10 years [13] since protection against pertussis from vaccination wanes after 4–12 years [14]. Patients with inflammatory bowel disease were recently shown to have reduced titers against pertussis [15]. Given the rise in the incidence of pertussis, the increased risk of infection in rheumatoid arthritis, and the reduced response of rheumatoid arthritis patients to some vaccines, it is important to determine if rheumatoid arthritis patients make a normal antibody response to pertussis vaccination.

The mechanism behind the altered response to some vaccines in rheumatoid arthritis is unclear. One possible mechanism is an inherently dysregulated immune system. People with rheumatoid arthritis generate autoantibodies against many different citrullinated proteins with overlapping specificity [16–19] and strong reactivity against citrulline itself [20], starting years prior to the diagnosis of rheumatoid arthritis [21]. This aberrant immune response extends to non-self antigens, since in rheumatoid arthritis, antibodies bind a citrullinated Epstein-Barr virus peptide more than the native peptide [22]. However, this citrulline-bias has never been evaluated in the context of vaccine response. Additionally, patients with rheumatoid arthritis take immune suppressing medications that could reduce the response to vaccination [6, 23–25]. Indeed, a brief discontinuation of methotrexate in rheumatoid arthritis patients can improve the response to vaccination against influenza [26]. The contributions of these mechanisms are unknown for the antibody response to pertussis vaccination in rheumatoid arthritis.
Here, we evaluate if antibody titers against pertussis in vaccinated rheumatoid arthritis patients are different than controls. We also examine demographics, immune suppressing medications, and reactivity against citrullinated pertussis to identify potential factors involved with the antibody response against pertussis in rheumatoid arthritis.

**Materials and methods**

**Human subjects**

Research was carried out and subjects gave written informed consent in compliance with the Declaration of Helsinki and as approved by the Institutional Review Board at the University of Wisconsin-Madison (#2015–0156). All clinical data and biologic samples were obtained from the University of Wisconsin (UW) Rheumatology Biorepository first described in [27]. The biorepository contains clinical data (obtained from the electronic medical record and subject self-report) and serum from subjects at least 18 years old receiving primary care and rheumatology care (for rheumatoid arthritis subjects) in an academic health system. Potential rheumatoid arthritis subjects were initially identified as individuals with two or more outpatient visits with rheumatoid arthritis associated ICD codes (ICD-9 codes 714.0–714.33, 714.9 or any ICD-10 code starting with M05, M06, or M08) within 24 months [28] or one visit and a positive anti-CCP (cyclic citrullinated peptide) antibody test. Rheumatoid arthritis diagnosis was confirmed based on manual review of the three most recent rheumatologist progress notes in the electronic medical record. Subjects were selected for this study if they had received a Tdap vaccine within 10 years of the blood collection for the biorepository. Rheumatoid arthritis subjects also had positive anti-CCP and rheumatoid factor tests with values twice the upper limit of normal. Since rituximab eliminates B cells preventing an antibody response, subjects using rituximab were excluded. Controls were matched by age and gender and excluded if they had any of the following diagnoses as determined by verbal screen or manual record review: systemic lupus erythematosus, Sjögren’s Syndrome, scleroderma, multiple sclerosis, type I diabetes, psoriasis or psoriatic arthritis, ankylosing spondylitis, reactive arthritis, ulcerative colitis, Crohn’s disease, cancer of the blood cells including leukemia or lymphoma.

For all subjects, the following variables were included as abstracted from the medical record for the time of serum collection unless otherwise noted: rheumatoid arthritis diagnosis, age, sex, smoking status and history, body mass index (BMI), Charlson comorbidity score [29], prescription of non-steroidal anti-inflammatory drugs (NSAIDs), and time since Tdap vaccination. For rheumatoid arthritis subjects, we also included age of rheumatoid arthritis diagnosis (self-reported since some subjects were diagnosed prior to inclusion in our electronic medical record), which was used to determine if a subject had rheumatoid arthritis at the time of vaccination (for subjects self-reporting rheumatoid arthritis diagnosis within six months of vaccination date, diagnosis date by the subject’s rheumatologist in the electronic medical record was used), and prescription of the following medications at the time of serum collection and vaccination as abstracted from the medical record: abatacept, hydroxychloroquine, leflunomide, methotrexate, sulfasalazine, and tumor necrosis factor (TNF) inhibitor (includes adalimumab, etanercept, and infliximab). No subjects were prescribed certolizumab or golimumab. Tofacitinib and tocilizumab were not included in the analysis since 4 and 0 subjects were prescribed this medication, respectively.

**Serum preparation**

For the biorepository, blood was collected from subjects into serum separator tubes (Greiner Bio-One, Monroe, USA) and centrifuged at 1300x g for 10 minutes. Serum was transferred to
a fresh tube and centrifuged at 2000x g for 5 minutes. The supernatant was then aliquoted and stored at -80˚C.

**Enzyme linked immunosorbent assay (ELISA)**

Pertussis and tetanus IgG titers were measured using *Bordetella pertussis* and Tetanus toxoid IgG ELISA kits according to the manufacturer’s instructions (Immuno-Biological Laboratories, Inc., Minneapolis, USA). Per manufacturer’s instruction, immunity to pertussis was defined as a pertussis IgG titer higher than 20 U/mL. For citrullination ELISAs, the precoated wells of pertussis and tetanus toxoid IgG ELISA kits were incubated with citrullination buffer (100mM Tris-HCl pH7.5, 1mM DTT, and 5mM CaCl$_2$) alone or with buffer and 0.01μg/mL peptidylarginine deiminase (PAD) 4 and 0.01μg/mL PAD2 overnight at 37˚C similar to previously [30]. Wells were washed three times before proceeding with the ELISA per manufacturer’s instruction. As a negative control, non-precoated 96 well plates (EIA/RIA Plate High Binding, Costar, Corning, USA) were exposed to buffer alone or buffer with PAD enzymes as above and used in ELISA to detect IgG in sera that binds to PAD enzymes. To assess citrullination efficiency, the pertussis and tetanus precoated wells exposed to buffer alone or buffer with PAD enzymes were washed three times before proceeding with the ELISA with these modifications: mouse anti-citrulline IgM (clone F95, EMD Millipore, Darmstadt, Germany) diluted 1:200 as primary antibody and anti-mouse IgM-HRP (SouthernBiotech, Birmingham, USA) diluted 1:5000 as secondary antibody.

**Statistical analysis**

Mean pertussis titers were compared between rheumatoid arthritis subjects and controls using a t-test and antibody levels against native versus citrullinated antigen by paired t-test. Comparison for proportional immunity between groups was measured with a Fisher’s exact test. To determine which clinical factors correlated with pertussis titer, univariate and multiple logistic regression analyses were performed. The multiple logistic regression models compared patients to median pertussis values across the entire cohort as well as proportions determined to be clinically immune to pertussis for odds ratio (OR) comparisons. For all statistical tests, $p<0.05$ was considered significant. Statistical analysis was performed using Stata version 14 (StataCorp LP, College Station, USA) and Prism (GraphPad Software, San Diego, USA).

**Results**

Ninety-eight rheumatoid arthritis patients and seventy-seven controls who received the Tdap vaccine within 10 years of blood collection were selected from the UW Rheumatology Biorepository. Controls and rheumatoid arthritis patients were similar with regards to age, sex, race/ethnicity, smoking status, BMI, time since vaccination, and age at vaccination (S1 Table). Time since vaccination demonstrated a trend towards being slightly shorter for rheumatoid arthritis subjects as compared to controls, by an average of 9.6 months ($p = 0.06$). Also, consistent with the one point given for a rheumatoid arthritis diagnosis in the scoring system, the Charlson comorbidity score was higher in rheumatoid arthritis subjects.

Sera from control and rheumatoid arthritis subjects were subjected to ELISA to detect IgG against pertussis and tetanus. As shown in Fig 1A (left panel), rheumatoid arthritis subjects had lower pertussis IgG titers compared to controls. Moreover, more than twice as many rheumatoid arthritis patients were considered not immune to pertussis than controls (22% versus 10%, $p = 0.03$, Fig 1A, right panel). As expected [10], no significant difference in tetanus IgG titers was observed between rheumatoid arthritis subjects and controls (Fig 1B).
Since pertussis immunity wanes after 4–12 years [14], we divided subjects by Tdap vaccination less than 5 years prior to serum collection or 5–10 years prior to serum collection and compared differences in pertussis IgG titers for rheumatoid arthritis versus control subjects. Rheumatoid arthritis subjects had only a trend towards reduced titers and reduced rates of immunity compared to controls <5 years after vaccination (Fig 1C). However, 5–10 years post-vaccination, rheumatoid arthritis subjects had about 50% lower titers compared to controls and 2.5 times more rheumatoid arthritis subjects were not immune (Fig 1D). Taken together, these data suggest that patients with rheumatoid arthritis have lower titers against pertussis and reduced rates of immunity against pertussis, particularly 5–10 years after vaccination.

To determine if clinical variables, such as use of immune suppressing medications, correlated with median pertussis titers, univariate and multiple logistic regression analyses were performed. When modeled for controls and rheumatoid arthritis subjects, a diagnosis of rheumatoid arthritis, female sex, and time since vaccination predicted lower than median pertussis titers in both univariate and multivariable analyses (Table 1). Obesity predicted higher than median titers in a univariate model, but this finding was not significant in the multivariable
model (Table 1). When rheumatoid arthritis subjects were evaluated separately, female sex was again predictive of lower than median pertussis titers (Table 2). Also, methotrexate use at the time of serum collection predicted lower than median pertussis titers in the univariate, but not the multivariable model (Table 2). In contrast, leflunomide use predicted higher than median pertussis titers in the univariate analysis only (Table 2). Time since vaccination again predicted lower than median pertussis titers and, interestingly, being diagnosed with rheumatoid arthritis at the time of vaccination (as opposed to not yet being diagnosed with rheumatoid arthritis

### Table 1. Predictors of greater than median pertussis titer in rheumatoid arthritis and control subjects (n = 98 rheumatoid arthritis and 77 controls).

| Predictor                      | Univariate |          |          | Multivariable |          |          |
|-------------------------------|------------|----------|----------|---------------|----------|----------|
|                               | OR         | 95% CI   | p        | OR            | 95% CI   | p        |
| Rheumatoid Arthritis          | 0.48       | (0.26, 0.89) | 0.02   | 0.29          | (0.13, 0.63) | 0.002   |
| Age                           | 1.00       | (0.97, 1.02) | 0.73   | 0.97          | (0.93, 1.01) | 0.12    |
| Sex: Female                   | 0.38       | (0.20, 0.75) | 0.005  | 0.34          | (0.16, 0.71) | 0.005   |
| Smoking Status (Never)        | Ref.       | Ref.     |          |              |          |          |
| Current                       | 1.53       | (0.53, 4.41) | 0.43   | 1.57          | (0.49, 5.05) | 0.45    |
| Former                        | 1.48       | (0.77, 2.87) | 0.24   | 1.34          | (0.62, 2.91) | 0.45    |
| BMI (Normal)                  | Ref.       | Ref.     |          |              |          |          |
| Overweight                    | 1.49       | (0.65, 3.44) | 0.35   | 1.34          | (0.53, 3.36) | 0.53    |
| Obese                         | 2.31       | (1.09, 4.93) | 0.03   | 1.94          | (0.85, 4.46) | 0.12    |
| Charlson Comorbidity Score    | 1.04       | (0.90, 1.20) | 0.57   | 1.19          | (0.92, 1.54) | 0.19    |
| NSAIDs (n = 77)               | 0.89       | (0.49, 1.61) | 0.70   | 0.92          | (0.46, 1.85) | 0.81    |
| Time since Vaccination        | 0.84       | (0.75, 0.95) | 0.007  | 0.83          | (0.72, 0.95) | 0.006   |

https://doi.org/10.1371/journal.pone.0217221.t001

### Table 2. Predictors of greater than median pertussis titer in rheumatoid arthritis (RA) (n = 98).

| Predictor                      | Univariate |          |          | Multivariable |          |          |
|-------------------------------|------------|----------|----------|---------------|----------|----------|
|                               | OR         | 95% CI   | p        | OR            | 95% CI   | p        |
| Age                           | 1.01       | (0.97, 1.04) | 0.68   | 0.99          | (0.93, 1.06) | 0.85    |
| Sex: Female                   | 0.28       | (0.12, 0.67) | 0.004  | 0.26          | (0.09, 0.75) | 0.01    |
| Smoking Status (Never)        | Ref.       | Ref.     |          |              |          |          |
| Current                       | 1.71       | (0.44, 6.62) | 0.43   | 1.84          | (0.36, 9.25) | 0.46    |
| Former                        | 1.61       | (0.66, 3.90) | 0.29   | 2.02          | (0.55, 7.45) | 0.29    |
| BMI (Normal)                  | Ref.       | Ref.     |          |              |          |          |
| Overweight                    | 2.35       | (0.75, 7.36) | 0.14   | 3.20          | (0.82, 12.50) | 0.10    |
| Obese                         | 2.48       | (0.87, 7.08) | 0.09   | 2.38          | (0.66, 8.58) | 0.19    |
| Charlson Comorbidity Score    | 1.09       | (0.90, 1.31) | 0.40   | 0.85          | (0.56, 1.30) | 0.46    |
| NSAIDs (n = 54)               | 1.27       | (0.57, 2.86) | 0.56   | 1.09          | (0.38, 3.14) | 0.87    |
| Time since Vaccination        | 0.80       | (0.67, 0.96) | 0.01   | 0.81          | (0.65, 1.02) | 0.08    |
| RA at Vaccination (n = 70)    | 3.67       | (1.33, 10.14) | 0.01  | 3.51          | (0.90, 13.72) | 0.07    |
| Abatacept (n = 7)             | 0.53       | (0.10, 2.89) | 0.47   | 0.34          | (0.05, 2.44) | 0.29    |
| Hydroxychloroquine (n = 23)  | 0.86       | (0.33, 2.24) | 0.76   | 0.84          | (0.21, 3.34) | 0.80    |
| Leflunomide (n = 20)          | 3.32       | (1.19, 9.28) | 0.02   | 3.50          | (0.78, 15.61) | 0.10    |
| Methotrexate (n = 53)         | 0.41       | (0.18, 0.94) | 0.04   | 0.71          | (0.21, 2.43) | 0.59    |
| Sulfasalazine (n = 7)         | 1.95       | (0.41, 9.21) | 0.40   | 4.54          | (0.41, 50.25) | 0.22    |
| TNF inhibitor (n = 35) *      | 1.53       | (0.67, 3.54) | 0.32   | 1.16          | (0.34, 3.95) | 0.82    |

* For TNF inhibitor users: 17 were prescribed methotrexate, 4 leflunomide, 5 hydroxychloroquine, and 1 sulfasalazine with some subjects taking more than one of these medications.

https://doi.org/10.1371/journal.pone.0217221.t002
at the time of vaccination) predicted greater than median pertussis titers in the univariate analysis with similar trends for both in the multivariable analysis.

We then performed univariate and multiple logistic regression analyses to identify clinical variables that correlate with immunity to pertussis according to cut-offs provided by the ELISA kit manufacturer. When modeled for controls and rheumatoid arthritis subjects combined, a diagnosis of rheumatoid arthritis and female sex predicted lower immunity to pertussis (Table 3), similar to the analysis for median pertussis titers (Table 1). Longer time since vaccination showed a trend towards predicting reduced immunity (Table 3), whereas time since vaccination clearly predicted lower than median titers (Table 1) perhaps due to titers falling over time, but not necessarily below the level required for immunity in this analysis. When modeled for rheumatoid arthritis subjects alone, female sex again predicted lower immunity (Table 4). Additionally, in multivariable analysis, methotrexate use at the time of serum collection predicted significantly lower immunity to pertussis (Table 4), similar to our univariate findings for median pertussis titers (Table 2). Of note, medications prescribed at the time of vaccination were also analyzed in place of medications prescribed at the time of serum collection for subjects diagnosed with rheumatoid arthritis at the time of vaccination, but no medication significantly correlated with either greater than median pertussis titer or pertussis immunity when prescribed at the time of vaccination (S2 and S3 Tables).

We next determined if there was evidence of an inherently dysregulated immune system affecting the antibody response to pertussis vaccination in rheumatoid arthritis. We were intrigued by the univariate finding that a diagnosis of rheumatoid arthritis, as opposed to not yet being diagnosed, at the time of Tdap vaccination predicted greater than median pertussis titers (Table 2). The subjects without a diagnosis of rheumatoid arthritis at vaccination would be diagnosed 0.1 to 6.6 years later. Given known delays in diagnosis [31] and the common presence of anti-citrullinated protein antibodies (ACPAs) a decade prior to diagnosis [21], the subjects without a rheumatoid arthritis diagnosis very likely had undiagnosed rheumatoid arthritis or preclinical rheumatoid arthritis at the time of vaccination. However, none of these subjects were receiving immune suppression, providing an opportunity to evaluate a role for immune dysregulation in vaccine response. Thus, we compared pertussis titers in subjects with versus without a diagnosis of rheumatoid arthritis at the time of vaccination and found significantly lower titers in subjects not yet diagnosed with rheumatoid arthritis (Fig 2A). The undiagnosed subjects had a longer time since vaccination than subjects diagnosed with

### Table 3. Predictors of pertussis immunity in rheumatoid arthritis and control subjects (n = 98 rheumatoid arthritis and 77 controls).

| Predictor                      | Univariate | Multivariable |
|--------------------------------|------------|---------------|
|                                | OR         | 95% CI        | p   | OR         | 95% CI        | p   |
| Rheumatoid Arthritis           | 0.40       | (0.17, 0.96)  | 0.04| 0.30       | (0.11, 0.81)  | 0.02|
| Age                            | 0.99       | (0.96, 1.03)  | 0.74| 0.99       | (0.94, 1.03)  | 0.55|
| Sex: Female                    | 0.30       | (0.10, 0.91)  | 0.03| 0.27       | (0.08, 0.85)  | 0.03|
| Smoking Status (Never)         | Ref.       | Ref.          |     |            |               |     |
| Current                        | 3.75       | (0.47, 30.02) | 0.21| 3.93       | (0.47, 33.19) | 0.21|
| Former                         | 1.44       | (0.59, 3.50)  | 0.42| 1.32       | (0.49, 3.51)  | 0.59|
| BMI (Normal)                   | Ref.       | Ref.          |     |            |               |     |
| Overweight                     | 1.03       | (0.38, 2.84)  | 0.95| 0.88       | (0.30, 2.59)  | 0.82|
| Obese                          | 1.73       | (0.66, 4.57)  | 0.27| 1.39       | (0.50, 3.87)  | 0.53|
| Charlson Comorbidity Score     | 0.97       | (0.81, 1.16)  | 0.74| 1.04       | (0.76, 1.42)  | 0.81|
| NSAIDs (n = 77)                | 1.03       | (0.47, 2.28)  | 0.94| 1.02       | (0.43, 2.43)  | 0.97|
| Time since Vaccination         | 0.91       | (0.78, 1.07)  | 0.26| 0.90       | (0.76, 1.06)  | 0.21|

https://doi.org/10.1371/journal.pone.0217221.t003
Table 4. Predictors of pertussis immunity in rheumatoid arthritis (RA) (n = 98).

|                              | Univariate |                     |     | Multivariable |                     |     |
|------------------------------|------------|---------------------|-----|---------------|---------------------|-----|
|                              | OR         | 95% CI              | p   | OR            | 95% CI              | p   |
| Age                          | 0.99       | (0.95, 1.03)        | 0.69| 0.99          | (0.93, 1.06)        | 0.81|
| Sex: Female                  | 0.34       | (0.11, 1.11)        | 0.07| **0.23**      | (0.06, 0.91)        | **0.04**|
| Smoking Status (Never)       | Ref.       | Ref.                |     | Ref.          | Ref.                |     |
| Current                      | 2.93       | (0.34, 25.21)       | 0.33| 3.91          | (0.36, 2.71)        | 0.26|
| Former                       | 1.12       | (0.40, 3.14)        | 0.84| 1.09          | (0.31, 3.92)        | 0.89|
| BMI (Normal)                 | Ref.       | Ref.                |     | Ref.          | Ref.                |     |
| Overweight                   | 1.35       | (0.39, 4.72)        | 0.64| 1.55          | (0.33, 7.29)        | 0.58|
| Obese                        | 1.43       | (0.46, 4.46)        | 0.54| 1.48          | (0.38, 5.69)        | 0.57|
| Charlson Comorbidity Score   | 1.00       | (0.80, 1.26)        | 0.97| 0.88          | (0.61, 1.27)        | 0.49|
| NSAIDs (n = 54)              | 1.03       | (0.40, 2.67)        | 0.95| 0.79          | (0.26, 2.37)        | 0.67|
| Time since Vaccination       | 0.89       | (0.73, 1.08)        | 0.24| 0.85          | (0.66, 1.09)        | 0.21|
| RA at Vaccination (n = 70)   | 1.22       | (0.44, 3.42)        | 0.70| 1.02          | (0.25, 4.13)        | 0.97|
| Abatacept (n = 7)            | 0.35       | (0.07, 1.71)        | 0.20| 0.24          | (0.03, 1.87)        | 0.17|
| Hydroxychloroquine (n = 23) | 1.06       | (0.34, 3.26)        | 0.93| 0.81          | (0.20, 3.22)        | 0.76|
| Leflunomide (n = 20)         | 0.84       | (0.27, 2.63)        | 0.76| 0.21          | (0.03, 1.29)        | 0.09|
| Methotrexate (n = 53)        | 0.47       | (0.17, 1.27)        | 0.14| **0.15**      | (0.03, 0.82)        | **0.03**|
| Sulfasalazine (n = 7) a      | -          | -                   | -   | -             | -                   | -   |
| TNF inhibitor (n = 35) b      | 1.25       | (0.45, 3.44)        | 0.67| 0.46          | (0.11, 1.98)        | 0.30|

*All subjects using sulfasalazine were immune to pertussis limiting calculations.

b For TNF inhibitor users: 17 were prescribed methotrexate, 4 leflunomide, 5 hydroxychloroquine, and 1 sulfasalazine with some subjects taking more than one of these medications.

https://doi.org/10.1371/journal.pone.0217221.t004

Fig 2. Lower pertussis titers in subjects not yet diagnosed with rheumatoid arthritis as compared to diagnosed with rheumatoid arthritis at the time of Tdap vaccination. A. Pertussis IgG titers were compared between subjects not yet diagnosed with rheumatoid arthritis (pre-RA) versus diagnosed with rheumatoid arthritis (RA) at the time of vaccination by t-test with averages and SEM graphed. B. Pertussis IgG titers and time since vaccination were graphed for pre-RA and RA groups with linear trendlines calculated. For all panels n = 28 pre-RA; n = 70 RA, *p<0.05.

https://doi.org/10.1371/journal.pone.0217221.g002
rheumatoid arthritis at the time of vaccination (average 1.8 years). Since a longer time since vaccination is also associated with lower pertussis titers (Fig 1 and Table 2), we divided subjects by diagnosis or no diagnosis of rheumatoid arthritis at the time of vaccination and, for each group, plotted pertussis titer versus time since vaccination. As shown in Fig 2B, there is a trend towards reduced titers over time in both groups as well as lower titers in undiagnosed subjects suggesting that both time since vaccination as well as untreated, pre-diagnosed rheumatoid arthritis correlate with lower pertussis titers.

Given these findings suggesting that immune dysregulation might contribute to lower pertussis titers in rheumatoid arthritis, we then hypothesized that rheumatoid arthritis patients would have antibodies that bind citrullinated pertussis, potentially reducing the normal immune response against native pertussis. To test this hypothesis, we treated the pertussis- and tetanus-coated ELISA plates with PAD2 and PAD4 and quantified citrullination by ELISA. As shown in Fig 3A and 3B, pertussis was efficiently citrullinated, but tetanus toxoid was not, likely due to the detoxification of tetanus toxin with formaldehyde to generate tetanus toxoid, a process which modifies arginines [32, 33]. We then demonstrated a lack of detectable binding of rheumatoid arthritis sera to the amount of PAD enzyme used to citrullinate (Fig 3C) and repeated our ELISAs to detect antibodies against citrullinated and native pertussis. Rheumatoid arthritis sera, and not control sera, had higher antibody binding to citrullinated compared to native pertussis (Fig 3D and 3E). Although we were unable to efficiently citrullinate tetanus toxoid in vitro and thus suspect that tetanus toxoid is also not citrullinated in vivo, we did see a trend towards increased citrullination and, thus, we determined if there was increased binding to the PAD-treated tetanus toxoid. As shown in Fig 3F and 3G, no increased binding was seen for rheumatoid arthritis or control sera against potentially citrullinated tetanus. Together, these data suggest that pertussis can be citrullinated and antibodies in rheumatoid arthritis bind citrullinated pertussis more than native pertussis, whereas tetanus toxoid is resistant to citrullination and thus is not likely to be a target of ACPAs.

Discussion

In this report, we have demonstrated that pertussis IgG titers are significantly lower in rheumatoid arthritis subjects compared to controls. Moreover, the percent of rheumatoid arthritis subjects considered immune to pertussis is two-fold lower than controls. Both of these findings were even more prominent in subjects who received the pertussis vaccine 5–10 years prior to serum collection. These results could suggest that hundreds of thousands of rheumatoid arthritis patients in the United States alone may be susceptible to pertussis infection, despite receiving the Tdap vaccine according to national guidelines. Further, our findings, combined with the extremely low vaccination rates against pertussis in rheumatoid arthritis patients in Germany [34], could suggest that as the numbers of pertussis infections rise in general, pertussis could become a significant problem for rheumatoid arthritis patients.

Limitations of our study include its retrospective design and that it does not examine infection rates in rheumatoid arthritis. Additionally, while our results reflect immune status according to the cut-offs of a commercial assay, no laboratory correlate of definitive pertussis protection is known. It will be important for future studies to examine rates of pertussis infection in patients with rheumatoid arthritis, particularly since we detected antibodies that react with citrullinated pertussis, which may or may not be protective. Moreover, prospective studies could determine if more frequent or higher dose vaccination would improve the antibody response to pertussis in rheumatoid arthritis.

We also provide evidence for potential mechanisms for these reduced titers, which are important for understanding how rheumatoid arthritis patients respond to immunization.
One possible mechanism for reduced pertussis IgG titers is the use of specific immune suppressing medications. In multivariable analysis, methotrexate use at the time of serum collection significantly correlated with lower pertussis immunity in rheumatoid arthritis (Table 4) with a similar finding of predicting less than median pertussis titers in univariate analysis (Table 2). These findings are similar to results seen for several studies evaluating methotrexate use and pneumococcal and influenza vaccines [6, 23, 24], although another study did not identify a correlation between methotrexate use and reduced vaccine response [8]. Additionally, a temporary pause in methotrexate usage at the time of influenza vaccination was shown to improve the response [26]. In contrast, we did not observe a correlation between methotrexate use at the time of vaccination and reduced response to pertussis (S2 and S3 Tables) potentially due to sample size, the retrospective nature of our study, or differences between the antibody response to pertussis versus influenza vaccines. Although the mechanism is not fully understood, methotrexate reduces T cell activity [35, 36]. Since acellular pertussis vaccines likely require T cells to establish humoral memory [37, 38], the depletion of T cells by methotrexate may contribute to the lower pertussis IgG titers in subjects taking this medication.

Interestingly, despite the high level of immune suppression attributed to TNF inhibiting medications, we did not see a correlation between TNF inhibitor use and reduced pertussis

---

**Fig 3.** Rheumatoid arthritis patients have higher IgG binding to citrullinated than native pertussis. Following citrullination of pertussis-coated (A) and tetanus toxoid-coated (B) wells, the extent of citrullination was quantified using an anti-citrulline antibody with the relative units (RU) compared for untreated versus citrullinated (CIT) wells. Averages with SEM are graphed (n = 5, *p*<0.05). Sera from rheumatoid arthritis (RA) patients (C, D, F) and controls (E, G) were subjected to ELISA to detect IgG binding against PAD enzymes (C), native and citrullinated (CIT) pertussis (D, E), or native and potentially citrullinated tetanus (F, G) with averages and SEM graphed. For panels C-G, control n = 30, RA n = 31, *p*<0.05.

https://doi.org/10.1371/journal.pone.0217221.g003
immunity or lower pertussis titers. This finding contrasts with a report that pertussis titers are lower in patients with inflammatory bowel disease using TNF inhibitors as compared to those using thiopurine [15]. For influenza and pneumonia vaccines, some studies report a correlation between TNF inhibiting medications and reduced titers, some studies report no reduction in titers related to TNF inhibitor use, and some studies suggest that reduced titers could be due to co-administration of additional immunomodulating agents with the TNF inhibiting medication [8, 24, 25, 39–44], as is the case in many of our subjects. The reason for this variability has not been thoroughly investigated. One possibility is that there may be differences among TNF inhibitors. For example, infliximab [41] and golimumab [25] are associated with reduced response to influenza and pneumococcal vaccines, whereas in separate studies, adalimumab, certolizumab, and etanercept use correlate with a normal antibody response to these vaccines [42–44]. Consistent with this theory, in our study, 34 of our 35 TNF inhibitor users were prescribed etanercept or adalimumab whereas in the inflammatory bowel disease study [15], 40% of the TNF inhibitor users were prescribed infliximab (F Caldera and M Hayney, University of Wisconsin-Madison, personal communication).

We also demonstrated that female sex significantly correlated with lower pertussis immunity and lower than median pertussis titers. This finding agrees with a study that found a correlation between reduced seropositivity for pertussis toxin and female sex in Hungary [45]. Sex differences in vaccine response occur for a variety of antigens although no clear pattern has been identified [46, 47]. Females have a greater response to influenza, hepatitis A and B, smallpox, and Brucella whereas males show greater response to pneumococcal polysaccharide and yellow fever vaccines [46, 48–54]. Both sexes respond similarly to the measles, mumps, and rubella (MMR) vaccine [55]. It remains unknown if sex differences in vaccine response are due to hormones, epigenetics, environment, microbiome, or cultural influences [47]. Future studies are needed to better characterize the role of sex in vaccine response and to optimize vaccine schedules based on gender and risk profiles.

Finally, our data suggest that an intrinsically dysregulated immune system may contribute to reduced pertussis titers in vaccinated rheumatoid arthritis subjects. We show that subjects vaccinated shortly prior to a diagnosis of rheumatoid arthritis (a disease phase associated with ACPAs as well as increased cytokines and chemokines [21, 56], but not immune suppressing medications) have lower pertussis titers than subjects diagnosed with rheumatoid arthritis at the time of vaccination. Moreover, we demonstrate that rheumatoid arthritis patients, but not controls, have greater binding to citrullinated than native pertussis, providing the first evidence that citrulline reactivity in rheumatoid arthritis extends to vaccine response. How antibodies against citrullinated pertussis develop and potentially contribute to reduced antibodies to native pertussis is not known. Vaccine adjuvants can attract neutrophils and induce neutrophil extracellular trap (NET) formation at the injection site [57]. Citrullinating PAD enzymes are released during NETosis and are present on NETs [58]. Thus, pertussis at the injection site could become citrullinated by PADs released from NETs. Alternatively, antigen processing can generate citrullinated peptides [59]. Rheumatoid arthritis patients may then preferentially generate antibodies against citrullinated as opposed to native pertussis antigens. Alternatively, given the cross-reactive repertoire of ACPAs in rheumatoid arthritis [16–20], pre-existing ACPAs could cross-react with pertussis citrullinated by NETs leading to clearance and reduced antigen availability for the generation of an immune response. Further work is needed to fully reveal this and other potential mechanisms that may alter the immune response to pertussis in rheumatoid arthritis.

Finally, in contrast to our pertussis results, we found that rheumatoid arthritis patients had normal titers against tetanus, as previously reported [10]. It is possible that immune suppressing medications do not sufficiently impair the immune system to reduce the antibody response
to the highly effective tetanus vaccine, but do reduce the response to the less efficacious pertussis vaccine. Additionally, there may be inherent differences in the immune response against pertussis as compared to tetanus in rheumatoid arthritis. In support of this theory, we found increased IgG binding to citrullinated pertussis, whereas tetanus toxoid could not be efficiently citrullinated in vitro and thus is unlikely to be citrullinated in vivo, making the development of anti-citrullinated tetanus antibodies or cross-reactivity of ACPAs with tetanus extremely unlikely. Future studies are needed to examine differences in the immune response to vaccination against these different pathogens in rheumatoid arthritis.

Conclusions
We have shown that vaccinated rheumatoid arthritis patients have lower titers against pertussis than controls with a potential role for female sex, methotrexate, and a citrulline-biased immune response. Our findings have potential clinical importance since they are the first to identify lower pertussis titers in rheumatoid arthritis, suggesting that these patients could be more susceptible to pertussis infection and might benefit from more frequent vaccination. Additionally, we provide the first evidence that a citrulline-biased immune system may complicate the response to immunization in rheumatoid arthritis, providing a novel mechanism for abnormal vaccine response.

Supporting information
S1 Table. A comparison of demographic and clinical characteristics between rheumatoid arthritis and control subjects.
(DOCX)

S2 Table. Predictors of greater than median pertussis titer in subjects diagnosed with rheumatoid arthritis at the time of vaccination including medications taken at the time of vaccination (n = 70).
(DOCX)

S3 Table. Predictors of pertussis immunity in subjects diagnosed with rheumatoid arthritis at the time of vaccination including medications taken at the time of vaccination (n = 70).
(DOCX)

Author Contributions
Conceptualization: Caitlyn L. Holmes, Chloe G. Peyton, Miriam A. Shelef.

Data curation: Amy M. Bier, Tobias Z. Donlon, Christie M. Bartels, Miriam A. Shelef.

Formal analysis: Caitlyn L. Holmes, Chloe G. Peyton, Fauzia Osman, Christie M. Bartels, Miriam A. Shelef.

Funding acquisition: Caitlyn L. Holmes, Miriam A. Shelef.

Investigation: Caitlyn L. Holmes, Chloe G. Peyton, Miriam A. Shelef.

Methodology: Caitlyn L. Holmes, Chloe G. Peyton, Fauzia Osman, Christie M. Bartels, Miriam A. Shelef.

Project administration: Caitlyn L. Holmes, Amy M. Bier, Tobias Z. Donlon, Miriam A. Shelef.

Resources: Amy M. Bier, Tobias Z. Donlon, Miriam A. Shelef.
**Supervision:** Christie M. Bartels, Miriam A. Shelef.

**Validation:** Caitlyn L. Holmes, Fauzia Osman, Miriam A. Shelef.

**Visualization:** Caitlyn L. Holmes.

**Writing – original draft:** Caitlyn L. Holmes, Miriam A. Shelef.

**Writing – review & editing:** Caitlyn L. Holmes, Chloe G. Peyton, Amy M. Bier, Tobias Z. Donlon, Fauzia Osman, Christie M. Bartels, Miriam A. Shelef.

**References**

1. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011; 63(3):633–9. https://doi.org/10.1002/art.30155 PMID: 21360492

2. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002; 46(9):2287–93. https://doi.org/10.1002/art.10524 PMID: 12355475

3. Ferreira I, Isenberg D. Vaccines and biologics. Ann Rheum Dis. 2014; 73(8):1446–54. https://doi.org/10.1136/annrheumdis-2014-205246 PMID: 24845388

4. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011; 70(3):414–22. https://doi.org/10.1136/ard.2010.137216 PMID: 21131643

5. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 2002; 34(2):147–53. https://doi.org/10.1086/338043 PMID: 11740700

6. Ribeiro AC, Guedes LK, Moraes JC, Saad CG, Aikawa NE, Calich AL, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011; 70(12):2144–7. https://doi.org/10.1136/ard.2011.152983 PMID: 21859696

7. Saletti S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNF-alpha blockers: safety and immunogenicity. Clin Immunol. 2010; 134(2):113–20. https://doi.org/10.1016/j.clim.2009.09.014 PMID: 19846344

8. Caporuscio S, Ieraci R, Valesini G, Teloni R, Mariotti S, Spinelli FR, et al. Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. Clin Immunol. 2018; 195:18–27. https://doi.org/10.1016/j.clim.2018.07.010 PMID: 30036638

9. Milanetti F, Germano V, Nisini R, Donatelli I, Di Martino A, Facchini M, et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009–10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol. 2014; 177(1):287–94. https://doi.org/10.1111/cei.12292 PMID: 24666311

10. Devey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 1987; 68(3):562–9. PMID: 3652524

11. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev. 2016; 29(3):449–86. https://doi.org/10.1128/CMR.00083-15 PMID: 27026954

12. National Center for Immunization and Respiratory Diseases DoBD. Pertussis Cases by Year (1922–2015). https://www.cdc.gov/pertussis/surv-reporting/cases-by-year.html2018.

13. Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, et al. Prevention of Pertussis, Teta

14. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005; 24(5 Suppl):S58–61. PMID: 15876927

15. Caldera F, Saha S, Wald A, Garmoe CA, McCrone S, Megna B, et al. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients. Dig Dis Sci. 2018; 63(6):1532–40. https://doi.org/10.1007/s10620-018-5043-2 PMID: 29594970
16. Corsiero E, Bombardieri M, Carliotti E, Pratesi F, Robinson W, Migliorini P, et al. Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullin histones of NETs. Ann Rheum Dis. 2016; 75(10):1866–75. https://doi.org/10.1136/annrheumdis-2015-208356 PMID: 26659717

17. Titcombe PJ, Wegerblad G, Sippel N, Zhang N, Shmagel AK, Sahstrom P, et al. Pathogenic citrulline-multispecific B cell receptor clades in rheumatoid arthritis. Arthritis Rheumatol. 2018.

18. Steen J, Forsstrom B, Sahstrom P, Odowd V, Israelsson L, Krishnamurthy A, et al. Human plasma cell derived monoclonal antibodies to post-translationally modified proteins recognize amino acid motifs rather than specific proteins. Arthritis Rheumatol. 2018.

19. Ioan-Facsinay A, el-Banouhd H, Scherer HU, van der Woude D, Menard HA, Lora M, et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis. 2011; 70(1):188–93. https://doi.org/10.1136/ard.2010.131102 PMID: 20736390

20. Ge C, Xu B, Liang B, Lonnblom E, Lundstrom SL, Zubarev RA, et al. Structural basis of cross-reactivity of anti-citrullinated protein antibodies. Arthritis Rheumatol. 2018.

21. Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autobody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012; 7(5):e35296. https://doi.org/10.1371/journal.pone.0035296 PMID: 22662108

22. Trier NH, Holm BE, Heiden J, Slot O, Locht H, Lindegaard H, et al. Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis. Sci Rep. 2018; 8(1):3684. https://doi.org/10.1038/s41598-018-22058-6 PMID: 29487382

23. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014; 66(7):1016–26.

24. Kapelanovic MC, Roseman C, Jonsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011; 63(12):3723–32. https://doi.org/10.1002/art.30580 PMID: 21834061

25. Migitka A, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate. Medicine (Baltimore). 2015; 94(52):e2184.

26. Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018; 77(6):898–904. https://doi.org/10.1136/annrheumdis-2018-213222 PMID: 29722931

27. Rebernik R, Fahmy L, Glover C, Bawadekar M, Shim D, Holmes CL, et al. DNA Area and NETosis Microscope Images. Biol Proced Online. 2018; 20:7. https://doi.org/10.1186/s12575-018-0072-y PMID: 29618953

28. Katz JN, Barrett J, Liang MH, Bacon AM, Kaplan H, Kieval RI, et al. Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum. 1997; 40(9):1594–600. https://doi.org/10.1002/art.1780400907 PMID: 9324013

29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373–83. PMID: 3558716

30. Damgaard D, Bawadekar M, Sencol L, Stensballe A, Shelef MA, Nielsen CH. Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3. PLoS One. 2018; 13(8):e0203214. https://doi.org/10.1371/journal.pone.0203214 PMID: 30161253

31. Barhamain AS, Magliah RF, Shaheen MH, Munassar SF, Falemban AM, Alshareef MM, et al. The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms. Open Access Rheumatol. 2017; 9:139–50. https://doi.org/10.2147/OARRR.S138830 PMID: 28814904

32. Metz B, Kersten GF, Hoogerhout P, Brugghe HF, Timmermans HA, de Jong A, et al. Identification of formaldehyde-induced modifications in proteins: reactions with model peptides. J Biol Chem. 2004; 279(8):6235–43. https://doi.org/10.1074/jbc.M310752200 PMID: 14638685

33. Pasteur S. Adacel Package Insert. In: Pasteur S, editor. www.fda.gov: Federal Drug Administration; 2019.

34. Krasselt M, Ivanov JP, Baerwald C, Seifert O. Low vaccination rates among patients with rheumatoid arthritis in a German outpatient clinic. Rheumatol Int. 2017; 37(2):229–37. https://doi.org/10.1007/s00296-016-3608-y PMID: 27878345
35. Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016; 12(12):731–42. https://doi.org/10.1038/nrrheum.2016.175 PMID: 2778491

36. Fairbanks LD, Rückermann K, Qi Y, Hawrylowicz CM, Richards DF, Swaminathan R, et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J. 1999; 342 (Pt 1):143–52.

37. Fedele G, Cassone A, Ausiello CM. T-cell immune responses to Bordetella pertussis infection and vaccination. Pathog Dis. 2015; 73(7).

38. Dirix V, Verschueren V, Vermeulen F, De Schutter I, Goetgebuer T, Locht C, et al. Both CD4⁺ and CD8⁺ lymphocytes participate in the IFN-γ response to filamentous hemagglutinin from Bordetella pertussis in infants, children, and adults. Clin Dev Immunol. 2012; 2012:795958. https://doi.org/10.1155/2012/795958 PMID: 2250536

39. Andrisani G, Frasca D, Romero M, Armuzzi A, Felice C, Marzo M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: effects of combined therapy with immunosuppressants. J Crohns Colitis. 2013; 7(4):301–7. https://doi.org/10.1016/j.crohns.2013.08.008 PMID: 24011513

40. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5 (7):851–6. https://doi.org/10.1016/cgh.2007.02.035 PMID: 17544875

41. Hagihara Y, Ohtsuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis. 2014; 8(3):223–33. https://doi.org/10.1016/j.crohns.2013.08.008 PMID: 24584918

42. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007; 34(2):722–9. PMID: 17304613

43. Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK. Vaccine responses in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004; 31(7):1356–61. PMID: 15229957

44. Torzsa P, Devadiga R, Tafalla M. Seroprevalence of Bordetella pertussis antibodies in adults in Hungary: results of an epidemiological cross-sectional study. BMC Infect Dis. 2017; 17(1):242. https://doi.org/10.1186/s12879-017-2356-2 PMID: 28376738

45. Rhodes K, Scott A, Markham RL, Monk-Jones ME. Immunological sex differences. A study of patients with rheumatoid arthritis, their relatives, and controls. Ann Rheum Dis. 1969; 28(2):104–20. https://doi.org/10.1136/ard.28.2.104 PMID: 4180579

46. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annu Rev Cell Dev Biol. 2017; 33:577–99. https://doi.org/10.1146/annurev-cellbio-100616-060718 PMID: 28992436

47. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annu Rev Cell Dev Biol. 2017; 33:577–99. https://doi.org/10.1146/annurev-cellbio-100616-060718 PMID: 28992436

48. Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, et al. Half- vs full-dose trivalent influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008; 168(22):2405–14. https://doi.org/10.1001/archinternmed.2008.513 PMID: 19064822

49. Chen XQ, Bülbül M, de Gast GC, van Loon AM, Nalin DR, van Hattum J. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. J Hepatol. 1997; 26(2):260–4. PMID: 9059944

50. Morris CA, Oliver PR, Reynolds F, Selkon JB. Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age. Epidemiol Infect. 1989; 103(3):387–94. https://doi.org/10.1017/s0950268800070470 PMID: 2530104

51. Kennedy RB, Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Ryan MA, et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine. 2009; 27(25–26):3319–23. https://doi.org/10.1016/j.vaccine.2009.01.086 PMID: 19200827

52. Brandão AP, de Oliveira TC, de Cunto Brandileone MC, Gonçalves JE, Yara TI, Simonsen V. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long-term-care residents in Brazil. Vaccine. 2004; 23(8):762–8. https://doi.org/10.1016/j.vaccine.2004.07.024 PMID: 15542200
54. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVA X and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002; 66(5):533–41. PMID: 12201587

55. Shohat T, Green MS, Nakar O, Ballin A, Duvdevani P, Cohen A, et al. Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Isr Med Assoc J. 2000; 2(3):192–5. PMID: 10774264

56. Kokkonen H, Soderstrom I, Rocklov J, Hallamns G, Lejon K, Dahlqvist SR. Up-Regulation of Cytokines and Chemokines Predates the Onset of Rheumatoid Arthritis. Arthritis & Rheumatism. 2010; 62(2):383–91.

57. Stephen J, Scales HE, Benson RA, Erben D, Garside P, Brewer JM. Neutrophil swarming and extracellular trap formation play a significant role in Alum adjuvant activity. NPJ Vaccines. 2017; 2:1. https://doi.org/10.1038/s41541-016-0001-5 PMID: 29263862

58. Spengler J, Lugonja B, Ytterberg AJ, Zubarev RA, Creese AJ, Pearson MJ, et al. Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid. Arthritis Rheumatol. 2015; 67(12):3135–45. https://doi.org/10.1002/art.39313 PMID: 26245941

59. Ireland JM, Unanue ER. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med. 2011; 208(13):2625–32. https://doi.org/10.1084/jem.20110640 PMID: 22162830